MD1568F1 - Method of treatment of the burn disease in the burn shock period - Google Patents
Method of treatment of the burn disease in the burn shock periodInfo
- Publication number
- MD1568F1 MD1568F1 MD20000058A MD20000058A MD1568F1 MD 1568 F1 MD1568 F1 MD 1568F1 MD 20000058 A MD20000058 A MD 20000058A MD 20000058 A MD20000058 A MD 20000058A MD 1568 F1 MD1568 F1 MD 1568F1
- Authority
- MD
- Moldova
- Prior art keywords
- burn
- hours
- treatment
- chloridephysiologic
- rest
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention refers to medicine, namely to burn disease treatment in the burn shock period. Summary of the invention consists in application on the burn wound of the bandage moistened with the mixture of medical remedies of following composition, mg/100 ml:hyaluronic acid 500...1000 furacin 20...40 novocaine 1000...1500 dimedrol 80...160 dexamethasone 8...16 heparin 5000...10000 UI contrical 5000...10000 UI sodium chloridephysiologic solution the rest. The bandage is applied to the burn wound in 6-10 hours during 48 hours and at the same time it is carried out the parenteral treatment including the administration of medical remedies composition at the following component ratio, mg/100 ml:hyaluronic acid 500...1000 dexamethason 8...16 glucose 5000...8000 sodium chloridephysiologic solution the rest, which is administered intraperitoneal in 10 hours in the dose of 25 ml/kg during 48 hours.Claims: 1
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MDA20000058A MD1568G2 (en) | 2000-03-28 | 2000-03-28 | Method of treatment of the burn disease in the burn shock period |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MDA20000058A MD1568G2 (en) | 2000-03-28 | 2000-03-28 | Method of treatment of the burn disease in the burn shock period |
Publications (2)
Publication Number | Publication Date |
---|---|
MD1568F1 true MD1568F1 (en) | 2000-12-31 |
MD1568G2 MD1568G2 (en) | 2001-06-30 |
Family
ID=19739571
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MDA20000058A MD1568G2 (en) | 2000-03-28 | 2000-03-28 | Method of treatment of the burn disease in the burn shock period |
Country Status (1)
Country | Link |
---|---|
MD (1) | MD1568G2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2449795C1 (en) * | 2010-11-16 | 2012-05-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации | Method of treating chronic pancreatitis |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MD481Z (en) * | 2011-08-09 | 2012-09-30 | Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова | Method for treating I-IIIA-degree burns |
-
2000
- 2000-03-28 MD MDA20000058A patent/MD1568G2/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2449795C1 (en) * | 2010-11-16 | 2012-05-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации | Method of treating chronic pancreatitis |
Also Published As
Publication number | Publication date |
---|---|
MD1568G2 (en) | 2001-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Waldhauser et al. | Efficiency and side effects of prostaglandin El in the treatment of erectile dysfunction | |
ES2164040T1 (en) | USE OF AGONISTS OF THE GLICINE UNION SITE OR INHIBITORS OF GLYCIN ABSORPTION FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS. | |
CA2321700A1 (en) | Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein | |
PT913156E (en) | USE OF PROTEIN C ACTIVATED TO TREAT HYPERCERAGULATE STATES ASSOCIATED WITH SEPSIA | |
GB0410266D0 (en) | Treatment of apoptosis | |
TW200806318A (en) | Uses of anti-insulin-like growth factor I receptor antibodies | |
Schirrmacher | Case of cobalt poisoning. | |
JPH01287041A (en) | Sustained release preparation | |
RU95101385A (en) | Products containing g-csf and tnf-binding protein | |
JP2004537500A5 (en) | ||
RU2007133435A (en) | METHOD OF COMBINED TREATMENT AND APPLICABLE FOR THIS COMBINATION OF MEDICINES | |
Valnes et al. | Trimipramine in the treatment of gastric ulcer | |
KR950031063A (en) | Using pravastatin to slow the progression of coronary atherosclerosis | |
MD1568F1 (en) | Method of treatment of the burn disease in the burn shock period | |
EP1108429A3 (en) | An improved amino acid composition for providing an amino acid supplement or protein substitute, particularly for the treatment and/or management of certain diseases | |
Cassuto et al. | Potent inhibition of burn pain without use of opiates | |
TNSN06072A1 (en) | Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep | |
JPH07506333A (en) | Pyridylguanidine compounds for the treatment of erectile dysfunction | |
CA2493208A1 (en) | Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure | |
CA2234936A1 (en) | Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine | |
JPH08501069A (en) | Treatment of pathological hypotension by combined use of cardiotonics and nitric oxide synthesis inhibitors | |
AR062894A1 (en) | FORMULATIONS FOR THERAPEUTIC ESTIMULATION HORMONE THERAPEUTIC ADMINISTRATION (THS) | |
Levine | Advances in the medical therapy of Peyronie's disease: a brief review. | |
KR930702985A (en) | Treatment of Esophageal Cancer | |
Tomlinson | Viagra and its use in cardiovascular disease. |